» Articles » PMID: 11117865

The Impact of Age and Sex on the Incidence of Glial Tumors in New York State from 1976 to 1995

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2000 Dec 16
PMID 11117865
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Object: In this study the authors describe secular trends in the incidence of three glial tumors--glioblastoma multiforme (GBM), astrocytoma not otherwise specified (ANOS), and anaplastic astrocytoma (AA)--in New York state from 1976 through 1995. They also describe the effect of age and sex on the relative risk (RR) for these tumors, specifically GBM.

Methods: Crude, age-, and sex-specific incidence rates were calculated for each tumor type from 1976 to 1995 by using data from the New York State Cancer Registry. Age-adjusted incidence rates were calculated by the direct standardization procedure, in which the 1970 United States Census Population Standard Million is used. The RR of GBM for the female population was calculated and plotted. Statistical comparisons were made using Pearson's correlation coefficient and regression analysis with the coefficient of variation.

Conclusions: The age-adjusted incidence of these three glial tumors increased during the study period. Increases in age-specific incidence of GBM were primarily limited to patients 60 years of age or older. The reasons for these increases cannot be fully explained with the data. Those in the female population had a lower risk of developing these tumors than those in the male. For GBM, the protective effect of sex was first evident at the approximate age of menarche, was greatest at the approximate age of menopause, and decreased in postmenopausal age strata. The overall protective effect of female sex and the described trend in RR for GBM in the female population suggests that sex hormones and/or genetic differences between males and females may play a role in the pathogenesis of this tumor.

Citing Articles

The influence of sex hormones on renal cell carcinoma.

Ladurner M, Lindner A, Rehder P, Tulchiner G Ther Adv Med Oncol. 2024; 16:17588359241269664.

PMID: 39175990 PMC: 11339752. DOI: 10.1177/17588359241269664.


Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.

Swellam M, Khalifa M, Nageeb A, Ezz El-Arab L, El-Mahdy M, El-Bahy K Int J Immunopathol Pharmacol. 2024; 38:3946320241250294.

PMID: 38686946 PMC: 11062227. DOI: 10.1177/03946320241250294.


Modular Hub Genes in DNA Microarray Suggest Potential Signaling Pathway Interconnectivity in Various Glioma Grades.

Orda M, Fowler P, Tayo L Biology (Basel). 2024; 13(4).

PMID: 38666818 PMC: 11048586. DOI: 10.3390/biology13040206.


An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah.

Earl E, Colman H, Mendez J, Jensen R, Karsy M Neurooncol Pract. 2023; 10(5):472-481.

PMID: 37720388 PMC: 10502782. DOI: 10.1093/nop/npad026.


Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.

Zhang H, Du Y, Qi L, Xiao S, Braun F, Kogiso M J Transl Med. 2023; 21(1):444.

PMID: 37415222 PMC: 10324131. DOI: 10.1186/s12967-023-04237-w.